Oncolytics Biotech Inc T.ONC

Leadership changes at Roche

[PeteZerria]

Roche's head of pharmaceuticals to leave company

 

ZURICH, Dec 12 (Reuters) - Roche (ROG.S) said on Monday the head of its pharmaceuticals division had decided to leave after 16 years with the Swiss drugmaker, heralding a wider reshuffle in addition to a planned CEO changeover early next year.

Bill Anderson, the former boss of Roche's Genentech unit, would quit at the end of the year "to pursue opportunities outside of Roche", with a successor due to be named by March 2023, Roche said in a statement. 

More: https://www.reuters.com/business/healthcare-pharmaceuticals/roche-names-new-ceo-with-schwan-set-become-chairman-2022-12-12/

[TMAZZ21]

Maybe he's coming to work for  Oncolytics Biotech

[Noteable]

Pharmaceuticals are OUT! Meanwhile Biologics and Biopharmaceuticals are IN ! And in Roche's case their failed bet on Alzheimer's disease at the expense of oncology has resulted in Anderson's sudden departure. As reported in the attached link ..." Bill Anderson, the former boss of Roche's Genentech unit, would quit at the end of the year "to pursue opportunities

[PeteZerria]

Sounds like internal conflict came to a head at Roche. "Let's focus on oncology and find some cures for cancer" "No, let's spend hundreds of millions testing this Alzheimer's drug" "Oh cr&p the the Alzheimer's drug doesn't work, who do we blame?" "Bill, you're fired" "OK, so what we need to do now is expand our oncology

[Proboscises]

Pharma CEOs pay a price for failed strategies. Billion $ bets that go south are not looked upon kindly. After some notable and costly failures I thinks these Pharmas would be looking for largely de-risked winners, especially de-risked winners in lucrative and hard to treat cancers. As mentioned earlier these Pharmas also fear missing out on winners that then go to their competitors.